The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study

被引：0
|
作者：
Francesco Russo
Michele Linsalata
Caterina Clemente
Benedetta D’Attoma
Antonella Orlando
Giovanna Campanella
Francesco Giotta
Giuseppe Riezzo
机构：
[1] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Biochemistry
[2] Medical Oncology Unit I.R.C.C.S. “Saverio de Bellis”,Laboratory of Experimental Pathophysiology
[3] Castellana Grotte,undefined
[4] Medical Oncology Unit I.R.C.C.S. “Giovanni Paolo II”,undefined
[5] National Institute for Digestive Diseases I.R.C.C.S. “Saverio de Bellis”,undefined
[6] Castellana Grotte,undefined
来源：
BMC Cancer | / 13卷
关键词：
Breast cancer; Chemotherapy-induced diarrhea; Epidermal growth factor; Intestinal permeability; Ghrelin; Glucagon-like peptide 2; Gut peptides; Zonulin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer
    Hiroshi Ishiguro
    Norikazu Masuda
    Nobuaki Sato
    Kenji Higaki
    Takashi Morimoto
    Yasuhiro Yanagita
    Makiko Mizutani
    Shoichiro Ohtani
    Koji Kaneko
    Tomomi Fujisawa
    Masato Takahashi
    Takayuki Kadoya
    Nobuki Matsunami
    Yutaka Yamamoto
    Shinji Ohno
    Toshimi Takano
    Satoshi Morita
    Sachiko Tanaka-Mizuno
    Masakazu Toi
    Breast Cancer Research and Treatment, 2020, 180 : 715 - 724
  • [22] A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer
    Ishiguro, Hiroshi
    Masuda, Norikazu
    Sato, Nobuaki
    Higaki, Kenji
    Morimoto, Takashi
    Yanagita, Yasuhiro
    Mizutani, Makiko
    Ohtani, Shoichiro
    Kaneko, Koji
    Fujisawa, Tomomi
    Takahashi, Masato
    Kadoya, Takayuki
    Matsunami, Nobuki
    Yamamoto, Yutaka
    Ohno, Shinji
    Takano, Toshimi
    Morita, Satoshi
    Tanaka-Mizuno, Sachiko
    Toi, Masakazu
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (03) : 715 - 724
  • [23] A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01)
    A Riccardi
    P Pugliese
    M Danova
    S Brugnatelli
    D Grasso
    M Giordano
    G Bernardo
    G Giardina
    S Fava
    G Montanari
    C Pedrotti
    G Trotti
    E Rinaldi
    M A Poli
    C Tinelli
    British Journal of Cancer, 2001, 85 : 141 - 146
  • [24] Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
    Wimmer, Kerstin
    Sachet, Monika
    Ramos, Cristiano
    Frantal, Sophie
    Birnleitner, Hanna
    Brostjan, Christine
    Exner, Ruth
    Filipits, Martin
    Bago-Horvath, Zsuzsanna
    Rudas, Margaretha
    Bartsch, Rupert
    Gnant, Michael
    Singer, Christian F.
    Balic, Marija
    Egle, Daniel
    Oehler, Rudolf
    Fitzal, Florian
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2023, 42 (01)
  • [25] Cyclophosphamide, epirubicin and fluorouracil chemotherapy-induced alteration of haemostasis markers in breast cancer patients
    Wang, Zhi
    Dang, Chengxue
    Zhu, Kun
    Zhang, Yong
    Chang, Dongmin
    Xia, Peng
    Song, Yongchun
    Li, Kang
    MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (05) : 1088 - 1092
  • [26] Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
    Kerstin Wimmer
    Monika Sachet
    Cristiano Ramos
    Sophie Frantal
    Hanna Birnleitner
    Christine Brostjan
    Ruth Exner
    Martin Filipits
    Zsuzsanna Bago-Horvath
    Margaretha Rudas
    Rupert Bartsch
    Michael Gnant
    Christian F. Singer
    Marija Balic
    Daniel Egle
    Rudolf Oehler
    Florian Fitzal
    Journal of Experimental & Clinical Cancer Research, 42
  • [27] Docetaxel alternating with epirubicin and cyclophosphamide: a feasibility study in breast cancer patients
    Huinink, WWT
    Lustig, V
    Dubbelman, R
    Hiemstra, A
    Rodenhuis, S
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : S23 - S25
  • [28] Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
    Fariba Mozaffari
    Christina Lindemalm
    Aniruddha Choudhury
    Helena Granstam-Björneklett
    Mats Lekander
    Bo Nilsson
    Marja-Leena Ojutkangas
    Anders Österborg
    Leif Bergkvist
    Håkan Mellstedt
    Cancer Immunology, Immunotherapy, 2009, 58 : 111 - 120
  • [29] Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
    Mozaffari, Fariba
    Lindemalm, Christina
    Choudhury, Aniruddha
    Granstam-Bjorneklett, Helena
    Lekander, Mats
    Nilsson, Bo
    Ojutkangas, Marja-Leena
    Osterborg, Anders
    Bergkvist, Leif
    Mellstedt, Hakan
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (01) : 111 - 120
  • [30] Effect of Fluorouracil-Epirubicin-Cyclophosphamide (FEC) chemotherapy on physiological bone marrow proliferation in breast cancer patients measured by 18F-FLT PET
    Mapelli, P.
    Aboagye, E.
    Al-Nahhas, A.
    Messa, C.
    Picchio, M.
    Gianolli, L.
    Coombes, C.
    Kenny, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S231 - S231
12345